Dashboard
Manage Tickers

UCBJYU C B


$ -3.50 (-4.17 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 445.65 $ 7.85 (1.79 %)
DIA $ 393.74 $ 6.69 (1.73 %)
SPY $ 528.43 $ 8.91 (1.72 %)
TLT $ 97.06 $ -0.98 (-1 %)
GLD $ 221.25 $ -0.20 (-0.09 %)
$ 80.38
-- x --
-- x --
-- - --
$ 34.47 - $ 86.02
28,361
na
nm
$ 0.63
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

theres-optimism-around-longboard-pharmaceuticals-anti-seizure-candidate-analyst-boosts-price-target
There's Optimism Around Longboard Pharmace...
01/02/2024 18:55:05

Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexic...

dianthus-monoclonal-antibody-on-promising-pathway-to-gaining-the-upper-hand---analyst
Dianthus' Monoclonal Antibody On Promising...
09/28/2023 19:33:57

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Ther...

skin-disease-focused-moonlake-immunotherapeutics-poised-to-outshine-rivals-analyst-asserts
Skin Disease Focused MoonLake Immunotherap...
08/31/2023 17:38:19

Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and 

fda-approves-rystiggo-the-only-treatment-for-two-most-common-subtypes-of-generalized-myasthenia-gravis-in-adults
FDA Approves Rystiggo: The Only Treatment ...
06/27/2023 17:47:04

The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG)...

cantor-on-moonlake-immunotherapeutics---initiates-on-inexpensive-valuation-strong-catalyst-path
Cantor On MoonLake Immunotherapeutics - In...
02/14/2023 18:02:14

the-week-ahead-in-biotech-may-30-june-4-fda-decision-for-etons-partnered-epilepsy-drug-asco-conference-gets-underway-and-more
The Week Ahead In Biotech (May 30-June 4):...
05/30/2022 18:03:17

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstandin...

ucbs-rare-childhood-epilepsy-drug-scores-fda-approval
UCB's Rare Childhood Epilepsy Drug Scores ...
03/28/2022 16:00:58

biogen-xbrane-enter-license-agreement-for-cimzia-referenced-biosimilar-xcimzane
Biogen-Xbrane Enter License Agreement For ...
02/08/2022 14:57:17

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have 

the-week-ahead-in-biotech-jan-23-29-roche-azurity-fda-decisions-jj-vertex-earnings-samsara-vision-ipo-and-more
The Week Ahead In Biotech (Jan 23-29): Roc...
01/23/2022 16:03:39

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. ...

ucbs-bispecific-marks-phase-3-win-for-second-psoriatic-arthritis-study
UCB's Bispecific Marks Phase 3 Win For Sec...
01/21/2022 17:10:34

UCB SA (OTC: UCBJF) 

benzingas-top-ratings-upgrades-downgrades-for-september-2-2021
Benzinga's Top Ratings Upgrades, Downgrade...
09/02/2021 14:02:18

 

Core News & Articles
JP Morgan Upgrades UCB to Overweight
09/02/2021 09:13:39

JP Morgan analyst Richard Vosser upgrades UCB (OTC:UCBJY) from Neutral to Overweight.

ucb-gets-eu-approval-for-bimekizumab-in-psoriasis
UCB Gets EU Approval For Bimekizumab In Ps...
08/25/2021 19:18:32

benzingas-top-ratings-upgrades-downgrades-for-august-23-2021
Benzinga's Top Ratings Upgrades, Downgrade...
08/23/2021 14:20:22

Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock perf...

Core News & Articles
UBS Upgrades UCB to Buy
08/23/2021 09:30:15

UBS analyst Laura Sutcliffe upgrades UCB (OTC:UCBJY) from Neutral to Buy.

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
07/23/2021 14:24:05

 

Core News & Articles
Deutsche Bank Initiates Coverage On UCB wi...
07/23/2021 09:26:46

Deutsche Bank analyst Emmanuel Papadakis initiates coverage on UCB (OTC:UCBJY) with a Buy rating.

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
07/09/2021 14:36:01

h2>Upgrades

Core News & Articles
Societe Generale Initiates Coverage On UCB...
07/09/2021 12:23:00

Societe Generale initiates coverage on UCB (OTC:UCBJY) with a Buy rating.

Core News & Articles
Stocks That Hit 52-Week Lows On Friday
10/04/2019 18:32:59

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION